West Pharmaceutical Services Appoints Michel Lagarde as New President and CEO
Summary
West Pharmaceutical Services has appointed Michel Lagarde, a seasoned healthcare and life sciences executive, as its new President and CEO, effective August 31, 2026, finalizing a previously announced leadership transition.
Key Events
-
New President and CEO Appointed
Michel Lagarde, formerly Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific, has been appointed President and Chief Executive Officer, effective August 31, 2026.
-
Leadership Transition Finalized
This appointment completes the succession plan following Eric M. Green's announced retirement. Lead Independent Director Robert F. Friel will become Board Chair.
-
Executive Compensation Package
Mr. Lagarde's compensation includes an annual base salary of $1,175,000, a target annual incentive of 125% of base salary, and initial equity awards totaling up to $18.6 million, including a matching grant for personal stock purchases.
Analysis
This 8-K finalizes a significant leadership transition for West Pharmaceutical Services, appointing Michel Lagarde as the new President and CEO. Lagarde brings extensive and highly relevant experience from Thermo Fisher Scientific and Patheon N.V., which is a positive signal for the company's strategic direction. His compensation package, including substantial equity awards and an incentive to personally invest in company stock, aligns his interests with long-term shareholder value. This appointment comes at a time when the company is performing strongly, trading near its 52-week high.
At the time of this filing, WST was trading at $316.75 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $22.3B. The 52-week trading range was $206.10 to $330.88. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.